VINC — Vincerx Pharma Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Brief: Vincerx Pharma Reports Second Quarter 2022 Financial Results And Provides A Corporate Update
Vincerx Pharma Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/Cdk9 Inhibitor Vip152 In Lymphoma
U.S. RESEARCH ROUNDUP- Carmax, Hanover Bancorp, Sherwin-Williams
Brief: Vincerx Pharma Provides Key Strategic Update
Vincerx Pharma Inc expected to post a loss of 93 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Costco Wholesale, Nielsen Holdings, Public Storage
Brief: Vincerx Pharma Posts Quarterly Loss Per Share $0.31
Brief: Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential Of Small Molecule-Drug Conjugate Vip236 In The Journal Cancers
Brief: Vincerx Pharma Inc Files For Mixed Shelf Of Upto $150 Million - SEC Filing
Brief: Vincerx Pharma Announces First Patient Dosed In Phase 1 Dose-Escalation Study Of VIP152 In Relapsed Or Refractory Chronic Lymphocytic Leukemia Or Richter Syndrome
Brief: Vincerx Pharma Presents Data On PTEFb/CDK9 Inhibitor VIP152 In DLBCL And CLL At 63rd American Society Of Hematology Annual Meeting
Brief: Vincerx Pharma Receives Orphan Drug Designation From European Commission For VIP152 For The Treatment Of Diffuse Large B-Cell Lymphoma
Brief: Vincerx Pharma Q3 Loss Per Share $1.39
Brief: Vincerx Pharma Files Prospectus Of Offer And Sale Of Up To 3.5 Million Shares
Brief: James Flynn Reports 6.56% Passive Stake In Vincerx Pharma Inc
Brief: Vincerx Pharma Reports $50 Mln Private Placement
Brief: Vincerx Pharma Reports Q2 Loss Per Share Of $0.12
Vincerx Pharma gains on Russell 3000 index inclusion